Sugi Predict

Sugi Predict / Compounds / SCHEMBL5338455

SCHEMBL5338455

SCHEMBL5338455

C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(c3ccc(CNC(N)=O)cc3)C[C@H]12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ ESR1 P03372 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ SLC6A4 P31645 1/20 0.39
▸ KCNH2 Q12809 1/20 0.39
▸ SLC29A1 Q99808 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.36
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ ADAM17 P78536 1/20 0.33
▸ CACNA1C Q13936 1/20 0.33
▸ F2 P00734 3/20 0.32
▸ TSHR P16473 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ SLC1A2 P43004 1/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ PTGS1 P23219 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14543143 0.91 KDM4E (0.42) LMNAKDM4EESR1CHRM1SLC6A4
SCHEMBL5338330 0.89 LMNA (0.41) LMNAKDM4EESR1CHRM1SLC6A4
SCHEMBL5341592 0.89 KDM4E (0.41) LMNAKDM4EESR1CHRM1SLC6A4
SCHEMBL6541980 0.89 LMNA (0.41) LMNAKDM4EESR1CHRM1SLC6A4
SCHEMBL6541975 0.89 LMNA (0.41) LMNAKDM4EESR1CHRM1SLC6A4
SCHEMBL5342286 0.88 LMNA (0.41) LMNAKDM4EESR1CHRM1SLC6A4
SCHEMBL14517643 0.88 KDM4E (0.42) LMNAKDM4EESR1CHRM1SLC6A4
SCHEMBL5353271 0.87 LMNA (0.34) LMNAKDM4EESR1CHRM1SLC6A4
SCHEMBL5343892 0.86 LMNA (0.45) LMNAKDM4EESR1CHRM1SLC6A4
SCHEMBL14517195 0.86 KDM4E (0.47) LMNAKDM4EESR1CHRM1SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7205291-B2 High mouth absorption; antibiotics against gramnegative, grampositive bacteria espscially Staphlococcus pneumonia, Hemophilus influenza DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-17 — — US disclosed
US-7205291-B2 High mouth absorption; antibiotics against gramnegative, grampositive bacteria espscially Staphlococcus pneumonia, Hemophilus influenza DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-17 — — US disclosed
US-7205291-B2 High mouth absorption; antibiotics against gramnegative, grampositive bacteria espscially Staphlococcus pneumonia, Hemophilus influenza DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-17 — — US disclosed
US-20050020566-A1 Novel carbapenem compounds DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-01-27 — — US disclosed
EP-1443047-A1 NOVEL CARBAPENEM COMPOUNDS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-08-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020566-A1 Novel carbapenem compounds HPN, PRSS1, BPGM LMNA 366/4885KDM4E 3734/4885ESR1 4684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.